Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
A Biomimetic Mn-Doped Polydopamine Nanoplatform for MRI-Enabled Synergistic Therapy to Enhance Lenvatinib Efficacy in
Wen Luo1,2, Yana Ma1,2, Weijia Zhu1,2
1Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
Abstract:
Liver cancer remains a major global public health threat, with high mortality. Lenvatinib is a tyrosine kinase inhibitor that has been used for the treatment of advanced liver cancer. However, its therapeutic efficacy is often limited by severe adverse effects and drug resistance. To overcome these challenge, we developed a biomimetic versatile nanoplatform based on Mn-doped polydopamine (PML@CM). Owing to their homologous tumor-targeting ability and pH-responsive drug release properties, PML@CM nanoparticles effectively improved the biocompatibility of lenvatinib and enhanced its tumor accumulation. Upon exposure to the tumor microenvironment, the released Mn2+ not only triggered chemodynamic therapy through Fenton-like reactions but also enabled magnetic resonance imaging (MRI). In addition, PML@CM nanoparticles exhibited an efficient photothermal conversion performance for tumor photothermal therapy. In conclusion, this nanoplatform provides a promising therapeutic strategy for MRI-enabled synergistic therapy against liver cancer.
Insights
A novel nanoplatform enhances lenvatinib treatment for liver cancer by improving drug delivery and enabling combined therapies. This approach offers a promising strategy for more effective liver cancer treatment with reduced side effects.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Liver cancer presents a significant global health challenge with high mortality rates.
- Lenvatinib, a tyrosine kinase inhibitor, is used for advanced liver cancer but faces limitations due to adverse effects and drug resistance.
Purpose of the Study:
- To develop a novel biomimetic nanoplatform for enhanced liver cancer therapy.
- To overcome the limitations of lenvatinib treatment through improved biocompatibility and targeted drug delivery.
Main Methods:
- Development of a Mn-doped polydopamine-based nanoplatform (PML@CM).
- Utilized homologous tumor-targeting and pH-responsive drug release properties.
- Investigated combined chemodynamic therapy, MRI, and photothermal therapy.
Main Results:
- PML@CM nanoparticles improved lenvatinib's biocompatibility and tumor accumulation.
- Released Mn²⁺ ions initiated Fenton-like reactions for chemodynamic therapy and enabled MRI.
- Demonstrated efficient photothermal conversion for photothermal therapy.
Conclusions:
- The developed nanoplatform offers a promising synergistic therapeutic strategy for liver cancer.
- This approach enables MRI-guided treatment and combines multiple therapeutic modalities.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...